on123300
Small moleculeexperimental
Clinical trial activity
3 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started May 13, 2021 (NCT04739293)
Timeline
2020s
- Jan 1, 2021
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- NUAK family SNF1-like kinase 1INHIBITOR
NUAK1 inhibitor
- Cyclin-dependent kinase 4INHIBITOR
CDK4 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
CN1CCN(c2ccc(Nc3ncc4cc(C#N)c(=O)n(C5CCCC5)c4n3)cc2)CC1- Mol. weight
- 429.53 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3115681 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06351644 | Phase 1/Phase 2 (Phase 2) | Sep 19, 2024 | Icahn School of Medicine at Mount Sinai |
| NCT05705505 | Phase 1/Phase 2 (Phase 2) | Mar 29, 2023 | Onconova Therapeutics, Inc. |
| NCT04739293 | Phase 1 | May 13, 2021 | Onconova Therapeutics, Inc. |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Onconova Therapeutics, Inc. | For profit | 2 | 2 | 2 | 2021 |
| Icahn School of Medicine at Mount Sinai | Academic/Hospital | 1 | 1 | 1 | 2024 |
2 organizations
Page 1 / 1